Austi, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Monoclonal Antibody Therapy Market Size & Growth Analysis:
According to SNS Insider, the global Monoclonal Antibody Therapy Market was valued at USD 259.36 billion in 2024 and is expected to reach USD 791.83 billion by 2032, expanding at a CAGR of 3.56% during the forecast period 2025–2032. The U.S. market alone is anticipated to grow from USD 75.61 billion in 2023 to USD 223.37 billion by 2032, demonstrating a strong 15.02% CAGR.
Get Free Sample Report of the Monoclonal Antibody Therapy Market: https://www.snsinsider.com/sample-request/3393
Monoclonal antibodies (mAbs) have become the therapeutic backbone for diseases such as cancer, autoimmune disorders, and infectious diseases. With continued advancements in protein engineering, bispecific antibodies, and checkpoint inhibitors, the treatment pipeline is expanding rapidly. The market is also being shaped by increased investment in personalized medicine, oncology therapeutics, and next-generation mAb platforms such as antibody-drug conjugates (ADCs) and Fc-engineered antibodies.
Market Overview
Monoclonal antibodies are lab-engineered proteins that mimic the immune system’s ability to fight off harmful pathogens and abnormal cells. Over the last decade, they’ve revolutionized treatment standards across oncology, rheumatology, and infectious diseases. Biopharmaceutical companies are pushing innovation with targeted immunotherapy, biospecific antibodies, and off-the-shelf CAR-T alternatives, bringing precision and scalability to the biologics space.
What’s fueling the market? Rising global prevalence of chronic diseases, strong biopharma pipelines, emergence of biosimilars, and speedy regulatory approvals in the U.S. and Europe. Alongside, investments in biomanufacturing infrastructure, especially in North America and Asia Pacific, are helping scale up production and meet growing demand.
Major Players Analysis Listed in this Report are:
- Roche Holding AG
- AbbVie Inc.
- Johnson & Johnson
- Amgen Inc.
- Bristol-Myers Squibb Company
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- AstraZeneca PLC
- GlaxoSmithKline plc (GSK)
- Sanofi S.A.
- Eli Lilly and Company
- Biogen Inc.
- Regeneron Pharmaceuticals Inc.
- Takeda Pharmaceutical Company Limited
- Genmab A/S
- UCB S.A.
- Seagen Inc.
- Bayer AG
- BeiGene Ltd. and other players.
Segment Analysis
Human mAbs Segment Dominated the Market, and Humanized mAbs Segment is Expected to Witness the Fastest Growth, by Type.
The human mAb segment led the monoclonal antibody therapy market in 2024 with 42.15% market share, owing to its high safety, more effectiveness, and low clearance rates as compared to murine and chimeric antibodies. These fully-human antibodies are prepared using sophisticated techniques such as transgenic mice and phage display, therefore reducing the likelihood of immune reactions.
Humanized mAb segment projected to be the fastest-growing segment during the forecast period due to its higher target-specificity and wider therapeutic scope. Humanized mAbs have been developed to reduce immunogenicity as long as they are based on mAb, stuff, and maintain high therapeutic efficacy when all the antigen binding sites from murine sources are retained and implanted into human antibody frameworks.
By Application, Cancer Segment Dominates the Market, Autoimmune Diseases to Witness the Fastest Growth
In 2024, the cancer segment accounted for the largest share of the monoclonal antibody therapy market, owing to the increasing use of monoclonal antibodies in cancer due to their targeted action, fewer side effects, and better patient outcomes. These therapies, including checkpoint inhibitors and antibody-drug conjugates, are now part of standard treatments for various cancers, including breast, lung, and colorectal.
The segment of autoimmune diseases is expected to be growing at the fastest rate during the forecast period as a result of the rising incidence of diseases such as rheumatoid arthritis, multiple sclerosis, and Crohn’s disease. The increasing understanding of immune pathways has allowed for the development of highly specific monoclonal antibodies that significantly improve symptom control and potentially disease modification.
Need Any Customization Research on Monoclonal Antibody Therapy Market, Enquire Now: https://www.snsinsider.com/enquiry/3393
Regional Trends
North America Dominates the Monoclonal Antibody Therapy Market, Asia Pacific Expected to Register Fastest Growth
North America held the largest share in the monoclonal antibody therapy market with 38% market share in 2024 due to an established healthcare system, a high presence of major biopharmaceutical companies, and strong R&D investment for advanced biologics. High awareness, early uptake of monoclonal antibody-based therapeutics, and favorable regulatory frameworks like the FDA’s fast-track and breakthrough therapy designations further boost the prospect for growth in the region.
The fastest growth in the monoclonal antibody therapy market is projected in Asia Pacific due to increased health care access, growing biotechnology industry, and incidence of cancer & autoimmune diseases. Nations such as China, India, and South Korea are becoming increasingly sophisticated in their clinical research and domestic biologics production.
Monoclonal Antibody Therapy Market Segmentation
By Type
- Human mAb
- Humanized mAb
- Chimeric mAb
- Murine mAb
By Application
- Cancer
- Autoimmune Diseases
- Infectious Diseases
- Hematological Disorders
- Ophthalmological Conditions
- Others (e.g., Cardiovascular, Respiratory)
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By End User
- Hospitals
- Specialty Clinics
- Research Institutes
- Homecare Settings
Monoclonal Antibody Therapy Market Report Scope
| Report Attributes | Details |
| Market Size in 2024 | US$ 22.16 billion |
| Market Size by 2032 | US$ 47.23 billion |
| CAGR | CAGR of 9.9% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Regional Analysis | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
Buy the Full Monoclonal Antibody Therapy Market Report (Single-User License) Now: https://www.snsinsider.com/checkout/3393
Unique Selling Propositions (USPs) of the Report:
- Monoclonal Antibody Clinical Pipeline Tracker
Assists the client in identifying prospective competition and collaboration by monitoring mAb candidates under development across indications and phases.
- Therapeutic Antibody Modality Evolution Matrix
Allows strategic planning by including evaluation of new antibody formats (bispecifics, ADCs) and their relative positioning within the therapy area landscape.
- Patent & IP Landscape Analysis
Aids in assessing market entry risks and pinpointing innovation white spaces through key patent holdings and patent expiration dates.
- Monoclonal Antibody Pricing & Reimbursement Benchmarks Available. Indices produced by the standard of care study clinicians
Facilitates pricing strategy and access planning by comparing the rise and fall of global pricing and reimbursement dynamics with specific examples of target leading therapies.
- Manufacturing and Supply Chain Intelligence
Inform make-or-buy and capacity planning decisions with insights on CMOs, bottlenecks, and scale challenges.
- Patient segregation and the use of biomarkers landscape
Aids in the design of personalized therapy strategies by illustrating the relevance of biomarkers and diagnostics in the correlation of treatments to patient subgroups.
- Regulatory Pathway Comparison
Facilitates go-to-market planning by comparing fast-track options across key regions and determining approval timescales.
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
